<DOC>
	<DOCNO>NCT00423579</DOCNO>
	<brief_summary>This study conduct compare efficacy , safety , tolerability ezetimibe/simvastatin 10/20 mg administer daily versus double dose simvastatin 40 mg patient hypercholesterolemia coronary heart disease .</brief_summary>
	<brief_title>The Effects Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg High Cholesterol Coronary Heart Disease Study ( P04039AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Subjects must document coronary heart disease ( CHD ) . For purpose study , CHD include one follow feature : document stable angina ( evidence ischemia exercise test ) ; history myocardial infarction ; history percutaneous coronary intervention [ PCI ] ( primarily PCI without stent placement ) ; symptomatic peripheral vascular disease ( claudication ) ; document history atherothrombotic cerebrovascular disease ; and/or document history unstable angina nonQ wave myocardial infarction . Subjects must demonstrate willingness participate study comply procedure sign write informed consent . History myocardial infarction ( heart attack ) . Subjects must &gt; = 18 year &lt; = 75 year age . Subjects must LDLC concentration &gt; = 2.6 mmol/L ( 100 mg/dL ) &lt; = 4.1 mmol/L ( 160 mg/dL ) time randomization ( Visit 3/Baseline Visit ) . Subjects must triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) ( Visit 3 Baseline Visit ) . Subject must currently take simvastatin 20 mg daily . Subjects must liver transaminase ( ALT [ alanine aminotransferase ] , AST [ aspartate aminotransferase ] ) &lt; 50 % upper limit normal , active liver disease , CK ( creatine kinase ) &lt; 50 % upper limit normal Visit 3 ( Baseline Visit ) . Clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator Visit 3 ( Baseline Visit ) . Subjects must maintain cholesterollowering diet exercise program least 4 week prior study willing continue diet exercise program study . Subjects must report stable weight history least 4 week prior entry study Visit 3 ( Baseline Visit ) . Women receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive , must maintain stable dose regimen least 8 week willing continue regimen duration study . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe intrauterine device [ IUD ] , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Subjects must free clinically significant disease hyperlipidemia coronary heart disease would interfere study evaluation . Subjects must understand able adhere dose visit schedule , must agree remain cholesterollowering diet exercise regimen duration study . Subjects whose body mass index ( BMI = weight [ kg ] /height2 [ ] ) &gt; = 35 kg/m^2 Visit 3 ( Baseline Visit ) . Subjects consume &gt; 14 alcoholic drink per week . ( A drink : beer , glass wine , single measure spirit ) . Any condition situation , opinion investigator , might pose risk subject interfere participation study . Women pregnant nursing . subject follow medical condition : Congestive heart failure define New York Heart Association ( NYHA ) Class III IV . Uncontrolled cardiac arrhythmia . Myocardial infarction , acute coronary insufficiency , coronary artery bypass surgery , angioplasty within 3 month Visit 3 ( Baseline Visit ) . Unstable severe peripheral artery disease within 3 month Visit 3 ( Baseline Visit ) . Newly diagnose currently unstable angina pectoris ( chest pain ) . Uncontrolled hypertension ( treat untreated ) systolic blood pressure &gt; 160 mm Hg diastolic &gt; 100 mm Hg Visit 3 ( Baseline Visit ) . Type I Type II diabetes mellitus . Uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein , i.e. , secondary cause hyperlipidemia , secondary hypercholesterolemia due hypothyroidism ( thyroid stimulate hormone [ TSH ] upper limit normal ) Visit 3 . Subjects history hypothyroidism stable therapy thyroid hormone replacement least 6 week eligible enrollment TSH level within normal limit Visit 3 ( Baseline Visit ) . Impaired renal function ( creatinine &gt; 2.0 mg/dL ) nephrotic syndrome Visit 3 ( Baseline Visit ) . Disorders hematologic , digestive , central nervous system include cerebrovascular disease degenerative disease would limit study evaluation participation . Known Human Immunodeficiency Virus ( HIV ) positive . Cancer within past 5 year ( except successfully treat basal squamous cell carcinoma ) . History mental instability , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . subject follow concomitant medication : Subjects observe designate washout period prohibit medication . Subjects stop take various prohibit medication minimum period time Visit 3 , include amiodarone hydrochloride ( 6 month ) probucol ( 12 month ) . Subjects currently consume large amount grapefruit juice ( &gt; 1 liter/day ) . Oral corticosteroid , unless use replacement therapy pituitary/adrenal disease subject stable regimen least 6 week prior Visit 3 ( Baseline Visit ) . Subjects currently use cardiovascular medication ( e.g . antihypertensive , antiarrhythmic ) stable regimen least 6 week prior Visit 3 ( Baseline Visit ) expect change study . Subjects currently use psyllium , fiberbased laxative , and/or overthecounter ( OTC ) therapy know affect serum lipid level ( phytosterol margarine ) , stable regimen least 5 week prior study entry Visit 3 ( Baseline Visit ) agree remain regimen throughout study . Subject currently use orlistat sibutramine . Subjects currently use amiodarone hydrochloride . Subjects currently use danazol . Subjects currently use coumarin anticoagulant ( warfarin ) . Subjects use ( Screening Visit / Visit 1 ) statin simvastatin 20 mg , ezetimibe alone combination statin ( include fix combination simvastatin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>